Palvella Therapeutics Inc (PVLA)

04:51 AM

Is Palvella Therapeutics Inc. meeting your algorithmic filter criteriaRisk Management & Daily Entry Point Alerts - newser.com

04:51 AM

03:09 AM

Can Palvella Therapeutics Inc. stock rebound after recent weaknessStop Loss & Daily Stock Momentum Reports - newser.com

03:09 AM

02:43 AM

Trend analysis for Palvella Therapeutics Inc. this weekQuarterly Portfolio Report & Daily Profit Focused Screening - newser.com

02:43 AM

01:34 AM

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $75.50 Consensus PT from Analysts - Defense World

01:34 AM

Oct 13, 2025

Can Palvella Therapeutics Inc. rally from current levelsWeekly Loss Report & Risk Managed Investment Strategies - newser.com

Oct 13, 2025

Oct 13, 2025

Can Palvella Therapeutics Inc. stock withstand economic slowdownBuy Signal & Accurate Entry/Exit Alerts - newser.com

Oct 13, 2025

Oct 13, 2025

Palvella Receives Second Year of FDA Grant Funding for Phase 3 Qtorin Trial - MarketScreener

Oct 13, 2025

Oct 13, 2025

What Fibonacci levels say about Palvella Therapeutics Inc. reboundWall Street Watch & Free Community Supported Trade Ideas - newser.com

Oct 13, 2025

Oct 13, 2025

U.S. FDA awards year two funds to Palvella's phase 3 Selva trial - MarketScreener

Oct 13, 2025

Oct 13, 2025

U.S. Food and Drug Administration Awards Year Two Proceeds - GlobeNewswire

Oct 13, 2025

Oct 13, 2025

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations - Yahoo Finance

Oct 13, 2025

Oct 11, 2025

Palvella Therapeutics (NASDAQ:PVLA) Shares Down 5.9%What's Next? - MarketBeat

Oct 11, 2025

Oct 11, 2025

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Oct 11, 2025

Oct 10, 2025

Is Palvella Therapeutics Inc. reversing from oversold territoryJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com

Oct 10, 2025

Oct 10, 2025

Palvella Therapeutics' (PVLA) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat

Oct 10, 2025

Oct 09, 2025

Canaccord Genuity raises Palvella Therapeutics stock price target to $90 on new indication - Investing.com Canada

Oct 09, 2025

Oct 09, 2025

Canaccord Genuity Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq

Oct 09, 2025

Oct 09, 2025

Can trapped investors hope for a rebound in Palvella Therapeutics Inc.Quarterly Profit Review & Risk Adjusted Buy and Sell Alerts - newser.com

Oct 09, 2025

Oct 09, 2025

Applying big data sentiment scoring on Palvella Therapeutics Inc.Swing Trade & Weekly Top Performers Watchlists - newser.com

Oct 09, 2025

Oct 09, 2025

Palvella Therapeutics Expands Phase 3 Trial to Younger Patients - MSN

Oct 09, 2025

Oct 09, 2025

Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MSN

Oct 09, 2025

Oct 08, 2025

Palvella Therapeutics Names David W. Osborne, Ph.D. as Chief Innovation Officer - MSN

Oct 08, 2025

Oct 07, 2025

Palvella Therapeutics (NASDAQ:PVLA) Trading 6.6% HigherHere's What Happened - MarketBeat

Oct 07, 2025

Oct 06, 2025

Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year HighHere's Why - MarketBeat

Oct 06, 2025

Oct 06, 2025

Tick level data insight on Palvella Therapeutics Inc. volatilityMarket Rally & AI Driven Price Predictions - newser.com

Oct 06, 2025

Oct 06, 2025

Can Palvella Therapeutics Inc. (PI6) stock deliver consistent EPS growthMarket Weekly Review & AI Powered Buy/Sell Recommendations - newser.com

Oct 06, 2025

Oct 06, 2025

How to interpret RSI for Palvella Therapeutics Inc. stock2025 Price Targets & Long-Term Capital Growth Strategies - newser.com

Oct 06, 2025

Oct 05, 2025

How to build a custom watchlist for Palvella Therapeutics Inc.Earnings Overview Report & Safe Investment Capital Preservation Plans - newser.com

Oct 05, 2025

Oct 05, 2025

Will Palvella Therapeutics Inc. bounce back from current supportTrade Analysis Summary & Detailed Earnings Play Alerts - newser.com

Oct 05, 2025

Oct 05, 2025

LifeSci Capital Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $90 - 富途牛牛

Oct 05, 2025

Oct 05, 2025

Strid Group LLC Lowers Stake in Palvella Therapeutics, Inc. $PVLA - MarketBeat

Oct 05, 2025

Oct 05, 2025

Will Palvella Therapeutics Inc. (PI6) stock beat Nasdaq index returnsWeekly Gains Summary & Step-by-Step Swing Trade Plans - newser.com

Oct 05, 2025

Oct 04, 2025

Truist Financial Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $80 - 富途牛牛

Oct 04, 2025

Oct 03, 2025

Published on: 2025-10-03 02:03:51 - newser.com

Oct 03, 2025

Oct 02, 2025

Truist Securities Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq

Oct 02, 2025

Oct 02, 2025

Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $80.00 - MarketBeat

Oct 02, 2025

Oct 01, 2025

Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Cutaneous Venous Malformations - MSN

Oct 01, 2025

Oct 01, 2025

Can Palvella Therapeutics Inc. (PI6) stock attract ESG investments2025 Biggest Moves & Community Trade Idea Sharing Platform - newser.com

Oct 01, 2025

Oct 01, 2025

Is Palvella Therapeutics (NASDAQ:PVLA) A Risky Investment? - 富途牛牛

Oct 01, 2025

Sep 30, 2025

Palvella Therapeutics Kicks Off Phase 2 Trial for Promising Cutaneous VM Treatment - MSN

Sep 30, 2025